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[9]. All of the above reasons led us to focus on the toxin 
B gene in order to detect all possible genetic situations 
in toxigenic strains. In contrast to some other published 
genetic methods based on hybridizations or single 
amplifications, we have designed a nested PCR which 
has allowed us to achieve 100% sensitivity. Specificity 
has been optimal, since no amplifications were detected, 
either on other species of Clostridium or in the entero- 
pathogens included in the study. In other published 
techniques, C. sordellii, whose toxin is highly homo- 
logous with the one produced by C. d @ d e  [l], has 
offered false-positive results by cross-reactions. In our 
case a positive amplification band has never been 
obtained within this microorganism. 
All strains included in this study were classified 
identically by both techniques, with the exception of 
strain no. 110, which was PCR negative and a toxin 
producer according to the cytotoxicity assay. Never- 
theless, its cytopathic effect on human fibroblasts is 
atypical and it was not inhibited by toxin B antitoxin, 
so it could have been the result of a cause unrelated to 
C. df ic i le  toxin B production. This finding still remains 
controversial; nevertheless, strain 110 was considered as 
non-cytotoxic and PCR negative when calculating 
sensitivities, predictive values, and false result rates. The 
1125-kb band corresponding to the first amplification 
reaction was occasionally seen. Probably, the amounts 
of this PCR product are at the limit of detection by 
agarose gel electrophoresis and so it is observed 
occasionally in cases where the reaction yield has been 
optimal. Usually in these cases the amount of the 
main amplification product (322-bp band) is slightly 
reduced, probably due to inhibition of the nested 
amplification reaction by an excess of DNA template 
in it [lo]. All our studied isolates of C. d@ale, with the 
exception of C. d@cile ATCC 9689, were isolated fiom 
significant clinical specimens. This may explain the 
high rate of toxigenicity encountered (over 93% of all 
C. df ic i le  clinical isolates included). 
Our approach for the detection of toxigenic strains 
of C. d@ale is easy both to perform and to interpret 
and offers excellent sensitivity and specificity. Some 
attempts have also been made on a reduced number of 
fecal specimens which showed adequate yields. Further 
studies are now ongoing. 
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Selection of rifampicin-resistant Mycobacferium 
fuberculosis does not occur in the presence of low 
concentrations of rifaximin 
C l i n  Microbiol Znfect 1997; 3: 147-151 
Rifaximin, an insoluble derivative of rifamycin-SV [l] 
that is very poorly absorbed fiom the gastrointestinal 
tract [2], has been proposed for the oral therapy of 
several bacterial enteric diseases [3-61. In fact, rifaximin 
is particularly efficacious in eradicating strains of 
Salmonella and Shigella spp. and Escherichia coli possess- 
ing different virulence factors [7]. Staphylococci, 
streptococci and other Gram-positive as well as Gram- 
negative, aerobic and anaerobic species are also 
inhibited by the compound [8-lo]. Mycobacteria 
are also killed in vitro, as would be expected of 
an antibiotic sharing the properties of the rifamycin 
Since rifampicin is widely used for treating tuber- 
culosis and other types of mycobacterial infections 
which are increasing worldwide [12], the aim of our 
family [ll]. 
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Figure 1 Growth rates of strains 1 to 5 of M. tuberculosis, expressed as growth indices as a function of time, when tested 
with four rifaximin concentrations (A, 6 ng/mL; B, 20 ng/mL; C, 90 ng/mL, D, 270 ng/mL), compared with growth 
indexes of controls (C1 to C5) in the absence of antibiotic. Treated cultures, solid lines; control, dotted lines. 
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Figure 1 continued 
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work was to investigate whether rifaximin could select 
mutants of Mycobacteriurn tuberculosis (showing cross- 
resistance to rifampicin) when used for the treatment 
of enteric infections in patients harboring M. tuber- 
culosis. Five M. tuberculosis strains, recently isolated in 
the &agnostic laboratory of our institute, were tested 
three came &om patients with pulmonary and two &om 
patients with renal tuberculosis. 
Sterile stock solutions of rifaximin and rifampicin 
(provided by Alfa Wassermann, Bologna, Italy) were 
pre-diluted in methanol and then in saline. Cultures 
grown on Lowenstein-Jensen solid medium (a modi- 
fied Middlebrook 7H12 medium) were inoculated into 
12B Bactec liquid medium, following standardized 
procedures [13]. M e r  appropriate incubation in Bactec 
12B, each culture was resuspended in the special 
dduting fluid recommended in the standardized 
method [13] and adjusted to a concentration of 1 x lo8 
CFU/mL. (McFarland number 1). These suspensions 
were used to inoculate all vials containing drugs 
(rifampicin and rifaximin) and drug-fiee control vials. 
Assessment of susceptibility or resistance to rifam- 
picin and rifaximin was performed in 12B medium (in 
4-mL amounts, in 20-mL glass vials with rubber septa 
and caps) [14]. Minimal inhibitory concentrations 
(MICs) of rifaximin and rifampicin were determined 
by exposing the microorganisms to graded concen- 
trations of drugs (&om 0.06 to 4 pg/mL). Vials were 
then incubated for 6 days in Bactec 460. M e r  ths  
period, the control cultures demonstrated the maxi- 
mum growth index value (999) and the MIC was 
recorded as the antibiotic concentration which had 
prevented any bacterial growth [15]. 
In order to simulate the conditions deemed to 
occur in vivo during an average course of rifaximin 
therapy (400 mglday, in three doses per day for 10 days) 
a suitable inoculum of each of the microorganisms was 
seeded into 12B vials containing 6, 20, 90 and 270 
ng/ml of rifiximin. The times taken to reach the 
maximum growth index value in the absence (control) 
and in the four different concentrations of the selecting 
drug are depicted in Figure 1. At 6 ng/mL and 20 
n g / d  of rifaximin the growth rates of control and 
treated cultures were approximately the same (Figure 
lA, and 1B). With an increase in the concentration of 
rifaximin to 90 ng/mL, a substantial lag of 4 to 5 days 
was apparent in the time needed for drug-treated 
cultures to reach the same growth index as that of the 
control broths (Figure 1C). At the highest concen- 
tration of rifaximin employed (270 ng/mL) growth in 
the first 10 to 13 days was extremely slow or altogether 
absent. Only after about 18 to 23 days did the treated 
cultures reach the growth index attained in about 10 
days by the untreated controls (Figure 1D). 
In our experimental approach the artificially high 
amounts of rifaximin employed were in large excess of 
the concentrations to be expected &om intestinal 
absorption, during an average course of therapy for 
enteric infections. Their remarkable effects on the 
physiology of the pathogens tested, as apparent h m  the 
slower growth rates observed in treated as opposed to 
control cultures, clearly indicate that these levels of 
drug act as sub-minimal inhibitory concentrations and 
might therefore express a powerful stimulus for the 
selection of resistant mycobacterial strains. In fact, with 
several pathogens, and possibly with mycobacteria, 
mutational resistance is not a consequence of a one-step 
event, and high-level resistance to drugs can be 
acquired only by a series of successive exposures to 
increasing concentrations of drugs [16]. Therefore we 
analyzed whether the different rifaximin concen- 
trations used in our work could have selected M. 
tuberculosis strains resistant to rifaximin and rifampicin. 
For this purpose the MICs of rifampicin and 
rifaximin were determined for the five M. tuberculosis 
strains before and after treatment with rifaximin. The 
results obtained (data not reported) showed that the 
MICs of rifampicin and rifaximin were identical for 
each strain, examined before and afier treatment with 
the Uerent  concentrations of rifaximin. The data 
clearly show that no pathogens resistant to both 
rifampicin and rifaximin were selected under our test 
conditions. Since the rifiximin concentrations used 
in our in vitro experiments were higher than those 
expected &om intestinal absorption, it is probable that 
the minimal amounts of rifaximin possibly resorbed into 
the systemic fluids after oral adrmnistration do not 
represent a level which wdl induce the selection of 
drug-resistant microorganisms. 
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